Regeneron shares data for multiple myeloma treatment
Betsy Goodfellow | December 8, 2023 | News story | Medical Communications | Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with relapsed/refractory (R/R) multiple myeloma (MM).
The trial demonstrated a 71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow up.
All patients treated with the 200mg dose experienced adverse events, with 85% experiencing Grade ≥3 events, the most common being cytokine release syndrome.
This data is expected to be submitted to the relevant regulatory authorities, including the US Food and Drug Administration (FDA) this year.
L Andres Sirulnik, MD PhD, senior vice president, Translational and Clinical Sciences, Haematology at Regeneron, commented: “MM remains an incurable disease, in which patients endure cycles of relapse and remission, resulting in a critical need for innovative medicines. With longer follow-up data on linvoseltamab, we’re seeing deep and durable responses with a complete response rate nearing 50% in a difficult-to-treat patient population who had received a median of five prior lines of therapy. Furthermore, in our trial, the regimen had a short monitoring time and a convenient, response-adapted administration schedule that enabled deep responders to go from every two-week to every four-week dosing. This regimen saved time for clinicians and patients, underscoring the potential for linvoseltamab as a patient-centric option in R/R MM.”
Betsy Goodfellow
Related Content
Regeneron announces presentations of new data on Eylea HD for retinal disease
Regeneron has presented data for Eylea HD (aflibercept) 8mg injection for retinal disease. The data …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
